Helse Stavanger, Stavanger Universitetssykehus

Stavanger N-4011

6 studies enrolling now · 10 studies all time

What they study most

Cardiovascular Diseases, Diabetes Mellitus, Type 2, Extrapulmonary Neuroendocrine Cancer (epNEC), Focal Segmental Glomerulosclerosis, Heart Failure, Hypertension, Kidney Disease, Chronic, Proteinuric Kidney Diseases, Pyoderma Gangrenosum, Systemic Sclerosis

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy — Recruiting now
• A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) — Recruiting now
• PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease — Recruiting now
• A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis — Recruiting now
• A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum — Recruiting now
• A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease — Completed
• A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms. — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms — Completed